GPI 1485 is a product candidate that belongs to a class of small molecule compounds called neuroimmunophilin ligands.
In preclinical experiments, neuroimmunophilin ligands have been shown to repair and regenerate damaged nerves without affecting normal, healthy nerves.
GPI 1485 is being studied in phase 2 clinical trials for the treatment of Parkinson's disease and post-prostatectomy erectile dysfunction and in pre-clinical development for HIV related dementia and neuropathy.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Eliglustat | The metabolism of Eliglustat can be decreased when combined with GPI-1485. |
| Ibrutinib | The metabolism of Ibrutinib can be decreased when combined with GPI-1485. |
| Cilostazol | The metabolism of Cilostazol can be decreased when combined with GPI-1485. |
| Colchicine | The metabolism of Colchicine can be decreased when combined with GPI-1485. |
| Iloperidone | The metabolism of Iloperidone can be decreased when combined with GPI-1485. |
| Retapamulin | The metabolism of Retapamulin can be decreased when combined with GPI-1485. |
| Tofacitinib | The metabolism of Tofacitinib can be decreased when combined with GPI-1485. |
| Vardenafil | The metabolism of Vardenafil can be decreased when combined with GPI-1485. |
| Eszopiclone | The metabolism of Eszopiclone can be decreased when combined with GPI-1485. |
| Zopiclone | The metabolism of Zopiclone can be decreased when combined with GPI-1485. |
| Lovastatin | The metabolism of Lovastatin can be decreased when combined with GPI-1485. |
| Alfuzosin | The metabolism of Alfuzosin can be decreased when combined with GPI-1485. |
| Alprazolam | The metabolism of Alprazolam can be decreased when combined with GPI-1485. |
| Warfarin | The serum concentration of Warfarin can be increased when it is combined with GPI-1485. |
| Acenocoumarol | The serum concentration of Acenocoumarol can be increased when it is combined with GPI-1485. |
| (R)-warfarin | The serum concentration of (R)-warfarin can be increased when it is combined with GPI-1485. |
| R,S-Warfarin alcohol | The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with GPI-1485. |
| S,R-Warfarin alcohol | The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with GPI-1485. |
| (S)-Warfarin | The serum concentration of (S)-Warfarin can be increased when it is combined with GPI-1485. |
| Midazolam | The serum concentration of Midazolam can be increased when it is combined with GPI-1485. |
| Tacrolimus | The serum concentration of Tacrolimus can be increased when it is combined with GPI-1485. |
| Atorvastatin | The metabolism of Atorvastatin can be decreased when combined with GPI-1485. |
| Aripiprazole | The metabolism of Aripiprazole can be decreased when combined with GPI-1485. |
| Aripiprazole lauroxil | The metabolism of Aripiprazole lauroxil can be decreased when combined with GPI-1485. |
| Azithromycin | The metabolism of Azithromycin can be decreased when combined with GPI-1485. |
| Ziprasidone | The metabolism of Ziprasidone can be decreased when combined with GPI-1485. |
| Chlorpromazine | The metabolism of Chlorpromazine can be decreased when combined with GPI-1485. |
| Albendazole | The metabolism of Albendazole can be decreased when combined with GPI-1485. |
| Cephalexin | The metabolism of Cephalexin can be decreased when combined with GPI-1485. |
| Doxazosin | The metabolism of Doxazosin can be decreased when combined with GPI-1485. |
| Norethisterone | The metabolism of Norethisterone can be decreased when combined with GPI-1485. |
| Fenofibrate | The metabolism of Fenofibrate can be decreased when combined with GPI-1485. |
| Atazanavir | The metabolism of Atazanavir can be decreased when combined with GPI-1485. |
| Rosuvastatin | The metabolism of Rosuvastatin can be decreased when combined with GPI-1485. |
| Drospirenone | The metabolism of Drospirenone can be decreased when combined with GPI-1485. |
| Allylestrenol | The metabolism of Allylestrenol can be decreased when combined with GPI-1485. |
| Zuclopenthixol | The metabolism of Zuclopenthixol can be decreased when combined with GPI-1485. |
| Roflumilast | The serum concentration of Roflumilast can be increased when it is combined with GPI-1485. |
| Lacosamide | The metabolism of Lacosamide can be decreased when combined with GPI-1485. |
| Linagliptin | The metabolism of Linagliptin can be decreased when combined with GPI-1485. |
| Vorapaxar | The metabolism of Vorapaxar can be decreased when combined with GPI-1485. |
| Suvorexant | The metabolism of Suvorexant can be decreased when combined with GPI-1485. |
| Netupitant | The metabolism of Netupitant can be decreased when combined with GPI-1485. |
| Tasimelteon | The metabolism of Tasimelteon can be decreased when combined with GPI-1485. |
| Nintedanib | The metabolism of Nintedanib can be decreased when combined with GPI-1485. |
| Tenofovir alafenamide | The metabolism of Tenofovir alafenamide can be decreased when combined with GPI-1485. |
| Dihydroergocornine | The metabolism of Dihydroergocornine can be decreased when combined with GPI-1485. |
| Duvelisib | The metabolism of Duvelisib can be decreased when combined with GPI-1485. |
| Gilteritinib | The metabolism of Gilteritinib can be decreased when combined with GPI-1485. |
| 9-aminocamptothecin | The metabolism of 9-aminocamptothecin can be decreased when combined with GPI-1485. |
| Methylprednisone | The metabolism of Methylprednisone can be decreased when combined with GPI-1485. |
| Dihydroergocristine | The metabolism of Dihydroergocristine can be decreased when combined with GPI-1485. |
| Dihydroergocryptine | The metabolism of Dihydroergocryptine can be decreased when combined with GPI-1485. |
| Medical Cannabis | The metabolism of Medical Cannabis can be decreased when combined with GPI-1485. |
| Elexacaftor | The metabolism of Elexacaftor can be decreased when combined with GPI-1485. |
| Tazemetostat | The metabolism of Tazemetostat can be decreased when combined with GPI-1485. |
| Fosaprepitant | The metabolism of Fosaprepitant can be decreased when combined with GPI-1485. |
| Lefamulin | The metabolism of Lefamulin can be decreased when combined with GPI-1485. |
| Methysergide | The metabolism of Methysergide can be decreased when combined with GPI-1485. |
| Meperidine | The metabolism of Meperidine can be decreased when combined with GPI-1485. |
| Ebastine | The metabolism of Ebastine can be decreased when combined with GPI-1485. |
| Terfenadine | The metabolism of Terfenadine can be decreased when combined with GPI-1485. |
| Cisapride | The metabolism of Cisapride can be decreased when combined with GPI-1485. |
| Isavuconazole | The metabolism of Isavuconazole can be decreased when combined with GPI-1485. |
| Pretomanid | The metabolism of Pretomanid can be decreased when combined with GPI-1485. |
| Pimavanserin | The metabolism of Pimavanserin can be decreased when combined with GPI-1485. |
| Estetrol | The metabolism of Estetrol can be decreased when combined with GPI-1485. |
| Infigratinib | The metabolism of Infigratinib can be decreased when combined with GPI-1485. |
| Cyclosporine | The serum concentration of Cyclosporine can be increased when it is combined with GPI-1485. |
| Dofetilide | The serum concentration of Dofetilide can be increased when it is combined with GPI-1485. |
| Theophylline | The serum concentration of Theophylline can be increased when it is combined with GPI-1485. |
| Carbamazepine | The serum concentration of Carbamazepine can be increased when it is combined with GPI-1485. |
| Sirolimus | The serum concentration of Sirolimus can be increased when it is combined with GPI-1485. |
| Quinidine | The serum concentration of Quinidine can be increased when it is combined with GPI-1485. |
| Phenprocoumon | The serum concentration of Phenprocoumon can be increased when it is combined with GPI-1485. |
| Busulfan | The serum concentration of Busulfan can be increased when it is combined with GPI-1485. |
| Pimozide | The serum concentration of Pimozide can be increased when it is combined with GPI-1485. |
| Amiodarone | The serum concentration of Amiodarone can be increased when it is combined with GPI-1485. |
| Aminophylline | The serum concentration of Aminophylline can be increased when it is combined with GPI-1485. |
| Paclitaxel | The serum concentration of Paclitaxel can be increased when it is combined with GPI-1485. |
| Dasatinib | The serum concentration of Dasatinib can be increased when it is combined with GPI-1485. |
| Fosphenytoin | The serum concentration of Fosphenytoin can be increased when it is combined with GPI-1485. |
| Digitoxin | The serum concentration of Digitoxin can be increased when it is combined with GPI-1485. |
| Everolimus | The serum concentration of Everolimus can be increased when it is combined with GPI-1485. |
| Dronedarone | The serum concentration of Dronedarone can be increased when it is combined with GPI-1485. |
| Cobimetinib | The serum concentration of Cobimetinib can be increased when it is combined with GPI-1485. |
| Temsirolimus | The serum concentration of Temsirolimus can be increased when it is combined with GPI-1485. |
| Idelalisib | The serum concentration of Idelalisib can be increased when it is combined with GPI-1485. |
| Ceritinib | The serum concentration of Ceritinib can be increased when it is combined with GPI-1485. |
| Tianeptine | The serum concentration of Tianeptine can be increased when it is combined with GPI-1485. |
| Osimertinib | The serum concentration of Osimertinib can be increased when it is combined with GPI-1485. |
| Ribociclib | The serum concentration of Ribociclib can be increased when it is combined with GPI-1485. |
| Dacomitinib | The serum concentration of Dacomitinib can be increased when it is combined with GPI-1485. |
| Alpelisib | The serum concentration of Alpelisib can be increased when it is combined with GPI-1485. |
| Astemizole | The serum concentration of Astemizole can be increased when it is combined with GPI-1485. |
| Lomitapide | The serum concentration of Lomitapide can be increased when it is combined with GPI-1485. |
| Siponimod | The serum concentration of Siponimod can be increased when it is combined with GPI-1485. |
| Methotrexate | The serum concentration of Methotrexate can be increased when it is combined with GPI-1485. |
| Vinorelbine | The serum concentration of Vinorelbine can be increased when it is combined with GPI-1485. |
| Vincristine | The serum concentration of Vincristine can be increased when it is combined with GPI-1485. |